According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758

Insulin Glargine Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
4.3	28.09.2024	9371564-00010	Date of first issue: 27.08.2021

SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1	Product identifier Trade name	:	Insulin Glargine Formulation
1.2	Relevant identified uses of th	ie s	ubstance or mixture and uses advised against
	Use of the Sub- stance/Mixture		Pharmaceutical
	Recommended restrictions on use	:	Not applicable
1.3	Details of the supplier of the	saf	ety data sheet
	Company	:	MSD 120 Moorgate EC2M 6UR London, United Kingdom
	Telephone	:	+44 (0) 2081548000
	E-mail address of person responsible for the SDS	:	EHSDATASTEWARD@msd.com

1.4 Emergency telephone number

1-908-423-6000

SECTION 2: Hazards identification

2.1 Classification of the substance or mixture

Classification (REGULATION (EC) No 1272/2008) as amended by GB-CLP Regulation, UK SI 2019/720, and UK SI 2020/1567)

Skin irritation, Category 2 Serious eye damage, Category 1 Specific target organ toxicity - repeated exposure, Category 2 H315: Causes skin irritation.H318: Causes serious eye damage.H373: May cause damage to organs through prolonged or repeated exposure.

2.2 Label elements

Labelling (REGULATION (EC) No 1272/2008) as amended by GB-CLP Regulation, UK SI 2019/720, and UK SI 2020/1567)

Hazard pictograms



According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



Insulin Glargine Formulation

Version 4.3	Revision Date: 28.09.2024		SDS Number: 9371564-0001	Date of last issue: 06.04.2024 0 Date of first issue: 27.08.2021
Signal word		:	Danger	
Hazard statements		:	H315 H318 H373	Causes skin irritation. Causes serious eye damage. May cause damage to organs through prolonged or repeated exposure.
Preca	autionary statements	:	Prevention P260 P264 P280	: Do not breathe dust. Wash skin thoroughly after handling. Wear protective gloves/ eye protection/ face pro- tection.
			Response: P305 + P35 P314 P332 + P31	i1 + P338 + P310 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rins- ing. Immediately call a POISON CENTER/ doctor. Get medical advice/ attention if you feel unwell.

Hazardous components which must be listed on the label: Insulin Glargine m-Cresol

2.3 Other hazards

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

May form explosive dust-air mixture during processing, handling or other means.

SECTION 3: Composition/information on ingredients

3.2 Mixtures

Components

Chemical name	CAS-No. EC-No. Index-No. Registration number	Classification	Concentration (% w/w)
Insulin Glargine	160337-95-1	STOT RE 2; H373 (Blood, Nervous system)	>= 90 - <= 100
m-Cresol	108-39-4 203-577-9 604-004-00-9	Acute Tox. 3; H301 Acute Tox. 3; H311 Skin Corr. 1B; H314 Eye Dam. 1; H318 Aquatic Chronic 3; H412	>= 3 - < 5

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



Insulin Glargine Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
4.3	28.09.2024	9371564-00010	Date of first issue: 27.08.2021

For explanation of abbreviations see section 16.

SECTION 4: First aid measures

4.1 Description of first aid measu	ires	5
General advice	:	In the case of accident or if you feel unwell, seek medical ad- vice immediately. When symptoms persist or in all cases of doubt seek medical advice.
Protection of first-aiders	:	First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).
If inhaled	:	If inhaled, remove to fresh air. Get medical attention if symptoms occur.
In case of skin contact	:	In case of contact, immediately flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Get medical attention. Wash clothing before reuse. Thoroughly clean shoes before reuse.
In case of eye contact	:	In case of contact, immediately flush eyes with plenty of water for at least 15 minutes. If easy to do, remove contact lens, if worn. Get medical attention immediately.
If swallowed	:	If swallowed, DO NOT induce vomiting. Get medical attention if symptoms occur. Rinse mouth thoroughly with water.
4.2 Most important symptoms an	d e	ffects, both acute and delayed
Risks	:	Causes skin irritation. Causes serious eye damage. May cause damage to organs through prolonged or repeated exposure.
4.3 Indication of any immediate n	ned	lical attention and special treatment needed
Treatment	:	Treat symptomatically and supportively.
SECTION 5: Firefighting meas	sure	es

5.1 Extinguish	ing media
----------------	-----------

Suitable extinguishing media	:	Water spray
		Alcohol-resistant foam



Insulin Glargine Formulation

Versi 4.3	ion	Revision Date: 28.09.2024		OS Number: 71564-00010	Date of last issue: 06.04.2024 Date of first issue: 27.08.2021
				Carbon dioxide (0 Dry chemical	CO2)
	Unsuita media	able extinguishing	:	None known.	
5.2 S	Special	hazards arising from	the	e substance or mi	xture
	Specifi fighting	c hazards during fire-	:	concentrations, a potential dust exp	dust; fine dust dispersed in air in sufficient nd in the presence of an ignition source is a plosion hazard. bustion products may be a hazard to health.
	Hazarc ucts	lous combustion prod-	:	Carbon oxides	
5.3 A	Advice	for firefighters			
	Specia for firef	I protective equipment ighters	:		e, wear self-contained breathing apparatus. tective equipment.
	Specifi ods	c extinguishing meth-	:	cumstances and Use water spray	g measures that are appropriate to local cir- the surrounding environment. to cool unopened containers. ged containers from fire area if it is safe to do

SECTION 6: Accidental release measures

6.1 Personal precautions, protective equipment and emergency procedures

F	Personal precautions	:	Use personal protective equipment. Follow safe handling advice (see section 7) and personal pro- tective equipment recommendations (see section 8).

6.2 Environmental precautions

Environmental precautions	: Avoid release to the environment.
	Prevent further leakage or spillage if safe to do so.
	Retain and dispose of contaminated wash water.
	If spillage enters rivers or watercourses, inform the Environ-
	ment Agency (emergency telephone number 0800 807060).

6.3 Methods and material for containment and cleaning up

Methods for cleaning up	: Sweep up or vacuum up spillage and collect in suitable con- tainer for disposal. Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air)
	with compressed air). Dust deposits should not be allowed to accumulate on surfac- es, as these may form an explosive mixture if they are re-
	leased into the atmosphere in sufficient concentration. Local or national regulations may apply to releases and dis-



Insulin Glargine Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
4.3	28.09.2024	9371564-00010	Date of first issue: 27.08.2021
		employed in the mine which reg Sections 13 an	aterial, as well as those materials and items e cleanup of releases. You will need to deter- julations are applicable. d 15 of this SDS provide information regarding national requirements.

6.4 Reference to other sections

See sections: 7, 8, 11, 12 and 13.

SECTION 7: Handling and storage

7.1 Precautions for safe handling

Technical measures :	Static electricity may accumulate and ignite suspended dust causing an explosion. Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.
Local/Total ventilation : Advice on safe handling :	Use only with adequate ventilation.
Hygiene measures :	Take care to prevent spills, waste and minimize release to the environment. If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contami- nated clothing before re-use.
7.2 Conditions for safe storage, in	cluding any incompatibilities
Requirements for storage : areas and containers	Keep in properly labelled containers. Keep tightly closed. Store in accordance with the particular national regulations.
Advice on common storage	 Do not store with the following product types: Strong oxidizing agents
7.3 Specific end use(s)	
Specific use(s) :	No data available



Insulin Glargine Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
4.3	28.09.2024	9371564-00010	Date of first issue: 27.08.2021

SECTION 8: Exposure controls/personal protection

8.1 Control parameters

Occupational Exposure Limits

dust of any kind

10 mg/m3 Value type (Form of exposure): TWA (Inhalable) Basis: GB EH40

4 mg/m3 Value type (Form of exposure): TWA (Respirable fraction) Basis: GB EH40

Components	CAS-No.	Value type (Form of exposure)	Control parameters	Basis
Insulin Glargine	160337-95- 1	TWA	3 μg/m3 (OEB 4)	Internal

Derived No Effect Level (DNEL)

Substance name	End Use	Exposure routes	Potential health ef- fects	Value
m-Cresol	Workers	Inhalation	Long-term systemic effects	3.5 mg/m3
	Workers	Inhalation	Acute systemic ef- fects	343 mg/m3
	Workers	Skin contact	Long-term systemic effects	0.5 mg/kg bw/day
	Workers	Skin contact	Acute systemic ef- fects	1.47 mg/kg bw/day
	Consumers	Inhalation	Long-term systemic effects	0.75 mg/m3
	Consumers	Inhalation	Acute systemic ef- fects	222 mg/m3
	Consumers	Skin contact	Long-term systemic effects	0.25 mg/kg bw/day
	Consumers	Skin contact	Acute systemic ef- fects	0.74 mg/kg bw/day
	Consumers	Ingestion	Long-term systemic effects	0.25 mg/kg bw/day
	Consumers	Ingestion	Acute systemic ef- fects	0.74 mg/kg bw/day

Predicted No Effect Concentration (PNEC)

Substance name	Environmental Compartment	Value	
m-Cresol	Fresh water	0.1 mg/l	
	Marine water	0.01 mg/l	
	Intermittent use/release	0.076 mg/l	
	Sewage treatment plant	1.14 mg/l	
	Fresh water sediment	0.71 mg/kg	
	Marine sediment 0.071 mg/k		



Insulin Glargine Formulation

Version 4.3	Revision Date: 28.09.2024	SDS Number: 9371564-00010	Date of last issue: 06.04.2024 Date of first issue: 27.08.2021	
		Soil	0.0831 mg/kg	ĺ

8.2 Exposure controls

Engineering measures

Ensure adequate ventilation, especially in confined areas.

Minimize workplace exposure concentrations.

Apply measures to prevent dust explosions.

Ensure that dust-handling systems (such as exhaust ducts, dust collectors, vessels, and processing equipment) are designed in a manner to prevent the escape of dust into the work area (i.e., there is no leakage from the equipment).

Personal protective equipment

Eye/face protection :		Wear the following personal protective equipment: Chemical resistant goggles must be worn. If splashes are likely to occur, wear: Face-shield Equipment should conform to BS EN 166
Hand protection		
Material	:	Chemical-resistant gloves
Remarks	:	Choose gloves to protect hands against chemicals depending on the concentration and quantity of the hazardous sub- stance and specific to place of work. Breakthrough time is not determined for the product. Change gloves often! For special applications, we recommend clarifying the resistance to chemicals of the aforementioned protective gloves with the glove manufacturer. Wash hands before breaks and at the end of workday.
Skin and body protection	:	Select appropriate protective clothing based on chemical re- sistance data and an assessment of the local exposure poten- tial. Skin contact must be avoided by using impervious protective clothing (gloves, aprons, boots, etc).
Respiratory protection	:	If adequate local exhaust ventilation is not available or expo- sure assessment demonstrates exposures outside the rec- ommended guidelines, use respiratory protection. Equipment should conform to BS EN 14387
Filter type	:	Combined particulates and organic vapour type (A-P)

SECTION 9: Physical and chemical properties

9.1 Information on basic physical and chemical properties

Appearance Colour Odour Odour Threshold	:	Crystalline powder white No data available No data available
рН	:	No data available
Melting point/freezing point	:	No data available

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



Insulin Glargine Formulation

Vers 4.3	sion	Revision Date: 28.09.2024		S Number: 1564-00010	Date of last issue: 06.04.2024 Date of first issue: 27.08.2021
		oiling point and boiling	:	No data available	
	range Flash p	oint	:	No data available)
	Evapor	ation rate	:	No data available)
	Flamma	ability (solid, gas)	:	May form explosi dling or other me	ve dust-air mixture during processing, han- ans.
		explosion limit / Upper bility limit	:	No data available)
		explosion limit / Lower bility limit	:	No data available	•
	Vapour	pressure	:	No data available)
	Relative	e vapour density	:	No data available)
	Density	,	:	No data available)
	Partition octanol	er solubility n coefficient: n-	::	No data available No data available No data available	9
	Decom	position temperature	:	No data available)
	Viscosi Visc	ty :osity, kinematic	:	No data available	9
	Explosi	ve properties	:	Not explosive	
	Oxidizir	ng properties	:	The substance or	r mixture is not classified as oxidizing.
9.2	9.2 Other information				
	Flamma	ability (liquids)	:	No data available	
	Molecu	lar weight	:	No data available	9
	Particle	size	:	No data available	

SECTION 10: Stability and reactivity

10.1 Reactivity

Not classified as a reactivity hazard.

10.2 Chemical stability

Stable under normal conditions.

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



Version 4.3	Revision Date: 28.09.2024		S Number: 71564-00010	Date of last issue: 06.04.2024 Date of first issue: 27.08.2021	
10.3 Possi	ibility of hazardous rea	actio	ons		
	dous reactions	:	May form explosive dust-air mixture during processing, han- dling or other means. Can react with strong oxidizing agents.		
10.4 Cond	itions to avoid				
Condi	tions to avoid	:	Heat, flames and Avoid dust forma		
10.5 Incon	npatible materials				
Mater	ials to avoid	:	Oxidizing agents		
10.6 Hazaı	dous decomposition	prod	ucts		
No ha	zardous decomposition	proc	lucts are known.		
SECTION	11: Toxicological ir	nforr	mation		
	mation on toxicologica				
	Information on likely routes of exposure		Inhalation Skin contact Ingestion Eye contact		
	e toxicity assified based on availa	able i	nformation.		
<u>Produ</u>	<u>ict:</u>				
Acute	oral toxicity	:	Acute toxicity esti Method: Calculati	mate: > 2,000 mg/kg on method	
Acute	dermal toxicity	toxicity : Acute toxicity estimate: > 2,000 mg/kg Method: Calculation method			
Comp	oonents:				
Insuli	n Glargine:				
	oral toxicity	:	Remarks: No data	a available	
Acute	inhalation toxicity	:	Remarks: No data	a available	
Acute	dermal toxicity	:	Remarks: No data	a available	
m-Cre	esol:				
Acute	oral toxicity	:	LD50 (Rat): 121 r Remarks: Based	ng/kg on data from similar materials	
Acute	inhalation toxicity	:	Assessment: Cor	rosive to the respiratory tract.	
Acute	dermal toxicity	:	LD50 (Rabbit): 30 Remarks: Based	1 mg/kg on data from similar materials	

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



Vers 4.3	sion	Revision Date: 28.09.2024		DS Number: 971564-00010	Date of last issue: 06.04.2024 Date of first issue: 27.08.2021
		orrosion/irritation			
	Compo	onents:			
	Insulin	Glargine:			
	Remar	ks	:	No data available	
	m-Cres	sol:			
	Specie Result	s	:	Rabbit Corrosive after 3	minutes to 1 hour of exposure
		s eye damage/eye irr s serious eye damage.		on	
		onents:			
	Insulin	Glargine:			
	Remar	ks	:	No data available	
	m-Cres	sol.			
	Specie		:	Rabbit	
	Result		:	Irreversible effects	s on the eye
	Respir	atory or skin sensitis	atio	on	
		ensitisation ssified based on availa	able	information.	
	-	atory sensitisation ssified based on availa	able	information.	
	Compo	onents:			
	Insulin Remar	Glargine: ks	:	No data available	
		cell mutagenicity ssified based on availa	able	information.	
	Compo	onents:			
	Insulin	Glargine:			
	Genoto	oxicity in vitro	:	Result: negative	rial reverse mutation assay (AMES) on data from similar materials
				Result: negative	o mammalian cell gene mutation test on data from similar materials

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



3	Revision Date: 28.09.2024	-	S Number: 71564-00010	Date of last issue: 06.04.2024 Date of first issue: 27.08.2021	
			Result: negative	omosome aberration test in vitro e d on data from similar materials	
m-Cr	esol:				
Genotoxicity in vitro		:		omosome aberration test in vitro Test Guideline 473	
				terial reverse mutation assay (AMES) Test Guideline 471 e	
Genotoxicity in vivo		:	Test Type: Mutagenicity (in vivo mammalian bone-marror cytogenetic test, chromosomal analysis) Species: Mouse Application Route: Ingestion Method: OECD Test Guideline 475 Result: negative		
Carci	nogenicity				
	lassified based on ava	ailable i	nformation		
Com	oonents:				
	oonents:				
Insul	in Glargine:		Rat		
Insul Speci	in Glargine: es	:	Rat 2 Years		
Insul Speci Expos NOA	in Glargine: les sure time EL	:	2 Years 0.455 mg/kg bo	ody weight	
Insul Speci Expo	in Glargine: les sure time EL	:	2 Years	ody weight	
Insul Speci Expos NOA	in Glargine: les sure time EL lt	:	2 Years 0.455 mg/kg bo	ody weight	
Insul Speci Expos NOAI Resu Speci	in Glargine: les sure time EL lt	: : :	2 Years 0.455 mg/kg bo negative Mouse 2 Years		
Insul Speci Expos NOAI Resu Speci Expos NOAI	in Glargine: les sure time EL lt les sure time EL	:	2 Years 0.455 mg/kg bo negative Mouse 2 Years 0.455 mg/kg bo		
Insul Speci Expos NOAI Resu Speci Expos	in Glargine: les sure time EL lt les sure time EL	:	2 Years 0.455 mg/kg bo negative Mouse 2 Years		
Insul Speci Expos NOAI Resu Speci Expos NOAI	in Glargine: les sure time EL lt les sure time EL		2 Years 0.455 mg/kg bo negative Mouse 2 Years 0.455 mg/kg bo		
Insul Speci Expos NOAI Resu Speci Expos NOAI Resu	in Glargine: sure time EL It es sure time EL It		2 Years 0.455 mg/kg bo negative Mouse 2 Years 0.455 mg/kg bo negative		
Insul Speci Expos NOAE Resu Speci Expos NOAE Resu m-Cr	in Glargine: sure time EL It es sure time EL It		2 Years 0.455 mg/kg bo negative Mouse 2 Years 0.455 mg/kg bo		
Insul Speci Expos NOAE Resu Speci Expos NOAE Resu m-Cr Speci Applic Expos	in Glargine: es sure time EL t es sure time EL t es cation Route sure time		2 Years 0.455 mg/kg bo negative Mouse 2 Years 0.455 mg/kg bo negative Mouse, males Ingestion 105 weeks		
Insul Speci Expos NOAL Resu Speci Expos NOAL Resu m-Cr Speci Applic Expos Resu	in Glargine: les sure time EL lt es sure time EL lt esol: cation Route sure time lt		2 Years 0.455 mg/kg bo negative Mouse 2 Years 0.455 mg/kg bo negative Mouse, males Ingestion 105 weeks equivocal	ody weight	
Insul Speci Expos NOAE Resu Speci Expos NOAE Resu m-Cr Speci Applic Expos	in Glargine: les sure time EL lt es sure time EL lt esol: cation Route sure time lt		2 Years 0.455 mg/kg bo negative Mouse 2 Years 0.455 mg/kg bo negative Mouse, males Ingestion 105 weeks equivocal		
Insul Speci Expos NOAL Resu Speci Expos NOAL Resu m-Cr Speci Applic Expos Resu	in Glargine: les sure time EL lt es sure time EL lt esol: les cation Route sure time lt arks		2 Years 0.455 mg/kg bo negative Mouse 2 Years 0.455 mg/kg bo negative Mouse, males Ingestion 105 weeks equivocal	ody weight	
Insul Speci Expos NOAE Resu Speci Expos Resu MOAE Resu Speci Applic Expos Resu Rema	in Glargine: ies sure time EL it ies sure time EL it esol: cation Route sure time it arks ies cation Route		2 Years 0.455 mg/kg bo negative Mouse 2 Years 0.455 mg/kg bo negative Mouse, males Ingestion 105 weeks equivocal Based on data Mouse, female Ingestion	ody weight from similar materials	
Insul Speci Expos NOAE Resu Speci Expos Resu Resu Resu Resu Resu Resu Resu Res	in Glargine: ies sure time EL it ies sure time EL it esol: ies cation Route sure time it arks ies cation Route sure time		2 Years 0.455 mg/kg bo negative Mouse 2 Years 0.455 mg/kg bo negative Mouse, males Ingestion 105 weeks equivocal Based on data Mouse, female Ingestion 106 - 107 week	ody weight from similar materials	
Insul Speci Expos NOAE Resu Speci Expos NOAE Resu Speci Applic Expos Resu Rema	in Glargine: ies sure time EL it ies sure time EL it esol: ies cation Route sure time it arks ies cation Route sure time it arks ies cation Route sure time it		2 Years 0.455 mg/kg bo negative Mouse 2 Years 0.455 mg/kg bo negative Mouse, males Ingestion 105 weeks equivocal Based on data Mouse, female Ingestion 106 - 107 week positive	bdy weight from similar materials	
Insul Speci Expos NOAE Resu Speci Expos Resu Resu Resu Resu Resu Resu Resu Res	in Glargine: ies sure time EL it ies sure time EL it esol: ies cation Route sure time it arks ies cation Route sure time it arks ies cation Route sure time it		2 Years 0.455 mg/kg bo negative Mouse 2 Years 0.455 mg/kg bo negative Mouse, males Ingestion 105 weeks equivocal Based on data Mouse, female Ingestion 106 - 107 week positive	ody weight from similar materials	

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



Insulin Glargine Formulation

Version 4.3	Revision Date: 28.09.2024		0S Number: 71564-00010	Date of last issue: 06.04.2024 Date of first issue: 27.08.2021	
me	nt		cinogen		
-	productive toxicity classified based on availa	able	information.		
<u>Co</u>	mponents:				
Species: Rat Application Route: Subcutar Fertility: NOAEL: 0.36 mg/kg Result: No effects on fertility		0.36 mg/kg body weight s on fertility cy/early embryonic development e: Subcutaneous 0.072 mg/kg body weight			
	Effects on foetal develop- : T ment S A D R S A D R R R R R		Test Type: Embryo-foetal development Species: Rat Application Route: Subcutaneous Developmental Toxicity: NOAEL: 0.36 mg/kg body weight Result: No effects on foetal development Species: Rabbit Application Route: Subcutaneous Developmental Toxicity: LOAEL: 0.072 mg/kg body weight Result: Fetotoxicity Remarks: The mechanism or mode of action may not be rele- vant in humans.		
	Cresol: acts on fertility	: Test Type: Two-generation reproduction toxicity study Species: Rat Application Route: Ingestion Result: negative			
Effe me	ects on foetal develop- nt	:	: Test Type: Prenatal development toxicity study (teratogenic Species: Rat Application Route: Ingestion Result: negative		

STOT - single exposure

Not classified based on available information.

STOT - repeated exposure

May cause damage to organs through prolonged or repeated exposure.

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



Version 4.3	Revision Date: 28.09.2024		DS Number: 71564-00010	Date of last issue: 06.04.2024 Date of first issue: 27.08.2021		
Com	ponents:					
Insul	in Glargine:					
Expo Targe	Exposure routes Target Organs Assessment		Ingestion Blood, Nervous system May cause damage to organs through prolonged or repeated exposure.			
Repe	eated dose toxicity					
Com	ponents:					
Insul	in Glargine:					
Expo	EL		Rat 0.5 mg/kg 1.5 mg/kg Subcutaneous 30 d Blood, Nervous	system		
m-Cr	esol:					
NOAI Appli Expo	Species : NOAEL : Application Route : Exposure time : Method :		Rat 150 mg/kg Ingestion 13 Weeks OECD Test Guideline 408			
-	ration toxicity lassified based on availa	able	information.			
Expe	rience with human exp	osi	ıre			
Com	ponents:					
Insul Inhala	in Glargine: ation	:	Target Organs: Symptoms: Hyp Nausea	Blood oglycemia, Headache, Sweating, Tremors,		
SECTION	N 12: Ecological infor	rma	tion			
12.1 Toxi	city					
	ponents:					
m-Cr						
	esoi: tity to fish	:	LC50 (Oncorhy Exposure time:	nchus mykiss (rainbow trout)): 8.6 mg/l 96 h		
	tic invertebrates EC50 (Daphnia pulex (Water flea)): > 99.5 mg/l Exposure time: 48 h					



Vers 4.3	sion	Revision Date: 28.09.2024		0S Number: 71564-00010	Date of last issue: 06.04.2024 Date of first issue: 27.08.2021		
	Toxicity to fish (Chronic tox- icity)		:		2 d ales promelas (fathead minnow) on data from similar materials		
		/ to daphnia and other invertebrates (Chron- ity)	:		21 d ia magna (Water flea) d on data from similar materials		
12.2	Persis	tence and degradabil	ity				
	Compo	onents:					
	m-Cres Biodeg	sol: radability	:	Result: Readily bi Biodegradation: Exposure time: 28 Method: OECD T	90 %		
12.3	Bioaco	cumulative potential					
	Compo	onents:					
	m-Cres	sol:					
	Bioaccu	umulation	:		us idus (Golden orfe) factor (BCF): 17 - 20		
	Partitio octanol	n coefficient: n- /water	:	log Pow: 1.96			
12.4		ty in soil					
40 E		a available s of PBT and vPvB as		amant			
12.5			5563	ssment			
	Produc Assess		:	to be either persis	ixture contains no components considered stent, bioaccumulative and toxic (PBT), or ad very bioaccumulative (vPvB) at levels of		
12.6	Other a	adverse effects					
	Produc Endocr tial	:t: ine disrupting poten-	:	ered to have ende	ixture does not contain components consid- ocrine disrupting properties for environment REACH Article 57(f).		



Insulin Glargine Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
4.3	28.09.2024	9371564-00010	Date of first issue: 27.08.2021

SECTION 13: Disposal considerations

13.1 Waste treatment methods	
Product	 Dispose of in accordance with local regulations. According to the European Waste Catalogue, Waste Codes are not product specific, but application specific. Waste codes should be assigned by the user, preferably in discussion with the waste disposal authorities. Do not dispose of waste into sewer.
Contaminated packaging	 Empty containers should be taken to an approved waste han- dling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.

SECTION 14: Transport information

14.1 UN number

ADN	:	Not regulated as a dangerous good
ADR	:	Not regulated as a dangerous good
RID	:	Not regulated as a dangerous good
IMDG	:	Not regulated as a dangerous good
ΙΑΤΑ	:	Not regulated as a dangerous good
14.2 UN proper shipping name		
ADN	:	Not regulated as a dangerous good
ADR	:	Not regulated as a dangerous good
RID	:	Not regulated as a dangerous good
IMDG	:	Not regulated as a dangerous good
ΙΑΤΑ	:	Not regulated as a dangerous good
14.3 Transport hazard class(es)		
ADN	:	Not regulated as a dangerous good
ADR	:	Not regulated as a dangerous good
RID	:	Not regulated as a dangerous good
IMDG	:	Not regulated as a dangerous good
ΙΑΤΑ	:	Not regulated as a dangerous good
14.4 Packing group		
ADN	:	Not regulated as a dangerous good
ADR	:	Not regulated as a dangerous good
RID	:	Not regulated as a dangerous good
IMDG	:	Not regulated as a dangerous good

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



Insulin Glargine Formulation

Version 4.3	Revision Date: 28.09.2024	SDS Number:Date of last issue: 06.04.20249371564-00010Date of first issue: 27.08.2021	
IATA (Cargo) IATA (Passenger)		Not regulated as a dangerous goodNot regulated as a dangerous good	
14.5 Environmental hazards Not regulated as a dangerous			
	al precautions for use	er	
14.7 Transport in bulk according Remarks		g to Annex II of Marpol and the IBC Code : Not applicable for product as supplied.	

SECTION 15: Regulatory information

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

Relevant EU provisions transposed through retained EU law

UK REACH List of restrictions (Annex 17)	:	Not applicable
UK REACH Candidate list of substances of very high concern (SVHC) for Authorisation	:	Not applicable
The Persistent Organic Pollutants Regulations (retained Regulation (EU) 2019/1021 as amended for Great Brit-	:	Not applicable
ain) Regulation (EC) on substances that deplete the ozone laver	:	Not applicable
UK REACH List of substances subject to authorisation (Annex XIV)	:	Not applicable
GB Export and import of hazardous chemicals - Prior Informed Consent (PIC) Regulation	:	Not applicable
Control of Major Accident Hazards Regulations 2015 (CC Not applicable	MA	\ Η)

Other regulations:

Take note of The Management of Health and Safety at Work Regulations 1999 (requirements relating to protection of young people at work contained in Regulation 19) and of Directive 94/33/EC on the protection of young people at work.

The components of this product are reported in the following inventories:

AICS	:	not determined
DSL	:	not determined
IECSC	:	not determined

15.2 Chemical safety assessment

A Chemical Safety Assessment has not been carried out.

SECTION 16: Other information

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



Insulin Glargine Formulation

Version 4.3	Revision Date: 28.09.2024		9S Number: 71564-00010	Date of last issue: 06.04.2024 Date of first issue: 27.08.2021	
Other information		:	Items where changes have been made to the previous vers are highlighted in the body of this document by two vertical lines.		
Full te	xt of H-Statements				
H301		:	Toxic if swallowed	1.	
H311		:	Toxic in contact with skin.		
H314	H314 :		Causes severe skin burns and eye damage.		
H318	H318 :		Causes serious eye damage.		
H373 :		:	May cause damage to organs through prolonged or repeated exposure if swallowed.		
H412	H412 :		Harmful to aquatic life with long lasting effects.		
Full text of other abbreviations		ons			
Acute	Tox.	:	: Acute toxicity		
Aquati	c Chronic	:	: Long-term (chronic) aquatic hazard		
Eye Da	am.	:	Serious eye damage		
Skin C	orr.	:	Skin corrosion		
STOT		:		an toxicity - repeated exposure	
GB EH		:	UK. EH40 WEL - Workplace Exposure Limits		
GB EH	40 / TWA	:	: Long-term exposure limit (8-hour TWA reference period)		

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - Agreement concerning the International Carriage of Dangerous Goods by Road; AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA -European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of very high concern; TCSI - Taiwan Chemical Substance Inventory; TECI -Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN

According to REACH Regulation (EC) No 1907/2006, as amended by UK REACH Regulations SI 2019/758



Insulin Glargine Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
4.3	28.09.2024	9371564-00010	Date of first issue: 27.08.2021

- United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

Further information

Sources of key data used to compile the Safety Data Sheet	:		data from raw material SDSs, OECD esults and European Chemicals Agen- u/
Classification of the mixture:			Classification procedure:
Skin Irrit. 2	H31	15	Calculation method
Eye Dam. 1	H318		Calculation method
STOT RE 2	H37	73	Calculation method

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

GB / EN